Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe?

被引：26

作者：

Belancic, Andrej ^{[1
]}

Kresovic, Andrea ^{[2
]}

Troskot Dijan, Marija ^{[3
]}

机构：

[1] Univ Hosp Ctr Rijeka, Dept Clin Pharmacol, Kresimirova 42, Rijeka 51000, Croatia

[2] Univ Hosp Ctr Rijeka, Div Gastroenterol, Dept Internal Med, Rijeka, Croatia

[3] Univ Hosp Ctr Rijeka, Div Endocrinol Diabet & Metab Dis, Dept Internal Med, Rijeka, Croatia

来源：

CLINICAL OBESITY | 2021年 / 11卷 / 02期

关键词：

antidiabetics; coronavirus; diabetes mellitus; glucagon-like peptide 1; obesity; GLP-1; RECEPTOR; GUT MICROBIOTA; LUNG-FUNCTION; WEIGHT-LOSS; 3.0; MG; LIRAGLUTIDE; OUTCOMES; OBESITY; HYPOGLYCEMIA; INFLAMMATION;

D O I：

10.1111/cob.12439

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The aim of the present manuscript is to discuss on potential pros and cons of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as glucose-lowering agents during COVID-19 pandemic, and what is more to evaluate them as potential candidates for the treatment of patients, affected by COVID-19 infection, with or even without diabetes mellitus type 2. Besides being important glucose-lowering agents, GLP-1RAs pose promising anti-inflammatory and anti-obesogenic properties, pulmonary protective effects, as well as beneficial impact on gut microbiome composition. Hence, taking everything previously mentioned into consideration, GLP-1RAs seem to be potential candidates for the treatment of patients, affected by COVID-19 infection, with or even without type 2 diabetes mellitus, as well as excellent antidiabetic (glucose-lowering) agents during COVID-19 pandemic times.

引用

页数：6

共 70 条

[1] Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety [J].

Akhtar, Saghir ;

Benter, Ibrahim F. ;

Danjuma, Mohammed, I ;

Doi, Suhail A. R. ;

Hasan, Syed S. ;

Habib, Abdella M. .

JOURNAL OF DRUG TARGETING, 2020, 28 (7-8) :683-699

[2]

[Anonymous], 2015, MED LETT DRUGS THER, V57, P89

[3] COVID-19 in people with diabetes: understanding the reasons for worse outcomes [J].

Apicella, Matteo ;

Campopiano, Maria Cristina ;

Mantuano, Michele ;

Mazoni, Laura ;

Coppelli, Alberto ;

Prato, Stefano Del .

LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (09) :782-792

[4] Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials [J].

Aroda, V. R. ;

Ahmann, A. ;

Cariou, B. ;

Chow, F. ;

Davies, M. J. ;

Jodar, E. ;

Mehta, R. ;

Woo, V ;

Lingvay, I .

DIABETES & METABOLISM, 2019, 45 (05) :409-418

[5] A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials [J].

Aroda, Vanita R. .

DIABETES OBESITY & METABOLISM, 2018, 20 :22-33

[6] Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study [J].

Astrup, Arne ;

Rossner, Stephan ;

Van Gaal, Luc ;

Rissanen, Aila ;

Niskanen, Leo ;

Al Hakim, Mazin ;

Madsen, Jesper ;

Rasmussen, Mads F. ;

Lean, Michael E. J. .

LANCET, 2009, 374 (9701) :1606-1616

[7] Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study) [J].

Bajaj, Harpreet S. ;

Venn, Karri ;

Ye, Chenglin ;

Patrick, Avril ;

Kalra, Shivani ;

Khandwala, Hasnain ;

Aslam, Nadeem ;

Twum-Barima, David ;

Aronson, Ronnie .

DIABETES CARE, 2017, 40 (02) :194-200

[8]

Belancic Andrej, 2020, Obes Med, V19, P100259, DOI 10.1016/j.obmed.2020.100259

[9]

Belancic Andrej, 2020, Obes Med, V20, P100302, DOI 10.1016/j.obmed.2020.100302

[10] Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial [J].

Blackman, A. ;

Foster, G. D. ;

Zammit, G. ;

Rosenberg, R. ;

Aronne, L. ;

Wadden, T. ;

Claudius, B. ;

Jensen, C. B. ;

Mignot, E. .

INTERNATIONAL JOURNAL OF OBESITY, 2016, 40 (08) :1310-1319

← 1 2 3 4 5 6 7 →